Harvard professor and serial entrepreneur Gregory Verdine has taken a venture partner position at WuXi Healthcare Ventures, the corporate venturing arm of China-based pharmaceutical company WuXi PharmaTech.
Verdine, a Harvard Medical School Professor, has developed a new kind of therapeutics called stapled peptides. They are undergoing clinical development and are being advanced to treat conditions thought to be ‘undruggable’.
In addition to his academic work, Verdine has been a founder or co-founder of biotechnology companies including: Enanta Pharmaceuticals, Tokai Pharmaceuticals, Wave Life Sciences, Gloucester Pharmaceuticals, Eleven Biotherapeutics and Aileron Therapeutics.
Verdine said: “WuXi Healthcare Ventures offers a genuinely unique and powerful platform from which to build global drug discovery companies focused on next-generation therapeutics.
“I am thrilled and honoured to join the team of exceptional individuals in this fund who are working together to develop transformative pharmaceutical solutions to the most vexing medical problems of our day.”
– Photo courtesy of Harvard University